Apricus Bio said that a total of 10 small molecule therapeutic drugs with known low solubility and/or permeability, according to the Biopharmaceuticals (BCS) Classification System, were selected for these studies, and represented the anti-inflammatory drugs, diuretics, anti-hypertensives, antibiotics, anti-psychotics, anti-Parkinson agents and proton pump inhibitors.
Apricus Bio president and CEO Bassam Damaj said that the early data shows that the inclusion of NexACT can improve the oral delivery of some small molecules by positively affecting their solubility, which affects absorption.
"Over time, this could open up exciting new partnership opportunities, especially for promising drug candidates that did not reach, or successfully pass through clinical development, because of poor solubility," Damaj said.
"Our goal is to make a major breakthrough in the utilis ation of NexACT to improve and/or enable the delivery of difficult-to-absorb compounds."